Binding molecules to tumor associated macrophages and methods of use
The CRV peptide selectively targets tumor-associated macrophages through RXRB, modulating their phenotype and enhancing cancer treatment by reducing immunosuppression and providing diagnostic capabilities.
Patent Information
- Application Number
- JP2024117915
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-08-10
- Filing Date
- 2024-07-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-08-08
AI Technical Summary
Tumor-associated macrophages (TAMs) create an immunosuppressive tumor microenvironment that prevents the immune system from recognizing and eliminating cancer cells, necessitating a targeted approach to modulate their activity.
Development of molecules, such as the cyclic peptide CRVLRSGSC, that selectively bind to tumor-associated macrophages (TAMs) via the retinoid X receptor beta (RXRB), conjugated with therapeutic or diagnostic agents for targeted delivery to tumors, allowing for the modulation of TAM phenotype, reduction, or detection within the tumor microenvironment.
The CRV peptide effectively targets TAMs, modulating their phenotype from M2 to M1, reducing their immunosuppressive effects, and enhancing cancer treatment efficacy while providing diagnostic capabilities.
Smart Images

Figure 2024167186000001_ABST
Abstract
Description
[Technical field]
[0001] Related Applications This application claims the benefit of U.S. Provisional Application No. 62 / 717,656, filed Aug. 10, 2018, which is incorporated by reference in its entirety herein.
[0002] Statement of Federally Funded Research This invention was made with Government support under R21EB022652 awarded by the National Institutes of Health (NIH). The Government has certain rights in the invention. [Background technology]
[0003] Macrophages are distributed throughout all major organs and play a central role in normal immune homeostasis and disease progression, such as cancer, and are key regulators within the tumor microenvironment. In many tumors, anti-inflammatory macrophages (alternatively activated or M2 subtype), also known as tumor-associated macrophages (TAMs), are responsible for generating an immunosuppressive tumor microenvironment that prevents the recognition and elimination of tumor cells by the immune system. Summary of the Invention
[0004] Described herein are molecules that preferentially bind and target tumor-associated macrophages (TAMs), pharmaceutical compositions thereof, and methods for the treatment and diagnosis of cancer and immunosuppressive tumor microenvironment.Furthermore, provided are pharmaceutical compositions comprising a tumor-associated macrophage (TAM)-binding molecule conjugated to a moiety and a delivery agent, and methods related to the use of such pharmaceutical compositions for cancer treatment, where the pharmaceutical compositions are cytolytic to TAMs, remove, reduce and / or neutralize TAMs, or repolarize TAMs from M2 phenotype to M1 phenotype, methods related to the use of such pharmaceuticals for cancer detection, and methods related to the use of such pharmaceuticals for the detection of TAMs or tumor microenvironment are provided.
[0005] In one aspect, a pharmaceutical composition is provided. In some embodiments, the pharmaceutical composition comprises a TAM binding molecule. In some embodiments, the pharmaceutical composition comprises a TAM binding molecule conjugated to a moiety. In some embodiments, the pharmaceutical composition comprises a TAM binding molecule conjugated to a moiety and a binding agent. In some embodiments, the TAM binding molecule binds to retinoid X receptor beta on the TAM. In some embodiments, the TAM binding molecule is a peptide, a ligand, an antibody, a non-IG domain, or a small molecule entity. In some embodiments, the TAM binding molecule is an antibody or an antigen-binding fragment thereof. In some embodiments, the antibody is an IgG, IgA, or IgM antibody. In some embodiments, the antibody is a single domain antibody. In some instances, the antibody is a chimeric antibody, a humanized antibody, or a human antibody. In other instances, the antigen-binding fragment is a Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, or a bispecific antibody. In other embodiments, the TAM binding molecule is a peptide. In some instances, the TAM binding peptide is cyclic. In other instances, the cyclic TAM-binding peptide comprises a) CRVLRSGSC, or b) CRVLRSGSC with at least one conservative amino acid substitution. In some embodiments, the moiety conjugated to the TAM-binding molecule is a therapeutic or diagnostic agent. In some instances, the moiety is a therapeutic agent, where the therapeutic agent is a cytotoxic agent, a chemotherapeutic agent, a protein, a peptide, an antibody, a growth inhibitory agent, a nucleic acid, or an anti-hormonal agent. In other instances, the therapeutic agent is a cytotoxic agent, where the cytotoxic agent is a ribosome-inactivating protein, a histone deacetylase (HDAC) inhibitor, a tubulin inhibitor, an alkylating agent, an antibiotic, an anti-tumor agent, an anti-proliferative agent, an antimetabolite, a topoisomerase I or II inhibitor, a hormone agonist or antagonist, an immunomodulatory agent, a DNA minor groove binding agent, or a radioactive agent. In other embodiments, the moiety is a diagnostic agent that is a label. In some instances, the diagnostic agent is a label, where the label is a fluorescent label, a chromogenic label, or a radioactive label. In some embodiments, the pharmaceutical composition is comprised of a TAM-binding molecule directly conjugated to a moiety. In other embodiments, the pharmaceutical composition is comprised of a TAM binding molecule indirectly conjugated to a moiety via a linker.In some instances, the delivery agent is a liposome, microsphere, nanoparticle, microemulsion, microcapsule, polymer matrix, hydrogel, or viral vector.
[0006] In another aspect, a method of treating cancer is provided. The method generally comprises administering to a subject the pharmaceutical composition described above. In some embodiments, the TAM binding molecule is cytolytic to tumor cells. In some embodiments, the TAM binding molecule inhibits tumor growth. In some embodiments, a method of treating cancer is provided, wherein the cancer is selected from the group consisting of brain cancer, kidney cancer, ovarian cancer, prostate cancer, lymphoma, breast cancer, colon cancer, lung cancer, squamous cell carcinoma of the head and neck, and melanoma. In some embodiments, the method is performed in which the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially. In some embodiments, the method is performed in which the pharmaceutical composition is administered in combination with a second therapeutic agent. In further embodiments, the method is performed in combination with a second therapeutic agent, wherein the second therapeutic agent is a cancer chemotherapeutic agent, radiation therapy, a cytotoxic agent, another antibody, an NSAID, a corticosteroid, a nutritional supplement (e.g., an antioxidant), or a combination thereof.
[0007] In another aspect, a method is provided for reducing the number of TAMs in a tumor microenvironment of a subject with cancer. The method generally includes a pharmaceutical composition as described above, wherein the pharmaceutical composition is cytolytic to TAMs.
[0008] In another aspect, a method is provided for eliminating immune suppression within a tumor microenvironment of a subject with cancer, the method generally comprising a pharmaceutical composition as described above, wherein the pharmaceutical composition removes, reduces and / or neutralizes TAMs.
[0009] In another aspect, a method is provided for repolarizing TAMs from an M2 phenotype to an M1 phenotype in a subject with cancer, the method generally comprising the pharmaceutical composition described above, wherein the pharmaceutical composition repolarizes TAMs from an M2 phenotype to an M1 phenotype.
[0010] In another aspect, a method of detecting cancer in a subject is provided, the method generally comprising administering to the subject a pharmaceutical composition as described above.
[0011] In another aspect, a method is provided for detecting TAMS within the tumor microenvironment of a subject having cancer, the method generally comprising administering to the subject a pharmaceutical composition as described above.
[0012] In another aspect, a method of detecting the tumor microenvironment in a subject is provided. The method generally comprises administering to the subject a pharmaceutical composition as described above.
[0013] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference. [Brief description of the drawings]
[0014] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the invention may be obtained by reference to the following detailed description which sets forth illustrative embodiments thereof, the principles of the invention being utilized and which is taken in conjunction with the accompanying drawings, in which:
[0015] Table 1 summarizes the tumors tested for in vivo migratory colonization of CRV. [Figure 1A] Figure 1A is a depiction of FAM peptide binding. In vitro binding of FAM peptide with different cell lines. Cells were incubated with FAM-CRV or FAM-GGS (10 μM) for 1 h at 4 °C and washed with PBS. Fluorescence was measured by flow cytometry. Compared to FAM-GGS, higher binding of FAM-CRV was found on J774, RAW and THP-1 differentiated macrophages, but not on 4T1 tumor cells. [Figure 1B]Figure 1B is a depiction of FAM peptide binding. Representative UV illumination images of FAM-CRV migratory colonization in various tissues in 4T1 breast cancer mice. 100 μg of FAM-CRV in 100 μL of PBS was injected intravenously into 4T1 mice for 1 hour of circulation. Tissues were collected after transcardial perfusion with PBS. [Figure 2A] Figure 2A depicts immunofluorescence staining of tissues with FAM peptide and CD31 with different migration and colonization times (5 min, 15 min, and 60 min). Tissue sections of 4T1 orthotopic tumor-bearing mice injected with FAM-CRV or FAM-GGS peptide were stained with anti-FITC (green) and anti-CD31 antibodies (red) and DAPI (blue). Migration and colonization results of FAM-CRV or FAM-GGS in tumors at different time points. Top row: Representation of whole tumor. Bottom row: Enlarged view of the area marked with white square in the top row. [Figure 2B] Figure 2B depicts immunofluorescence staining of tissues with FAM peptide and CD31 with different migration and colonization times (5 min, 15 min, and 60 min). Tissue sections of 4T1 orthotopic tumor-bearing mice injected with FAM-CRV or FAM-GGS peptide were stained with anti-FITC (green) and anti-CD31 antibodies (red) and DAPI (blue). Distribution of FAM-CRV in other organs. FAM-CRV signal washed out over time. [Diagram 3]Figure 3 depicts the association of FAM-CRV with tumor macrophages. A) Immunofluorescence staining of 4T1 mouse tissues for FAM-CRV and macrophage markers. Tissue sections were stained with anti-FITC (green), anti-CD11b, anti-F4 / 80 or anti-CD68 antibodies (red) and DAPI (blue). Scale bar: 100 μm. B-D) Binding of FAM-CRV or FAM-GGS with cells isolated from various organs of ex vivo 4T1 mice. Cells were incubated with FAM-CRV or FAM-GGS, CD11b, CD68, and F4 / 80 primary and secondary antibodies for 1 h at 4 °C. Afterwards, cells were washed and analyzed by flow cytometry. B: Selective binding of FAM-CRV to tumor cells compared to blood and spleen cells. C: Binding of FAM-CRV or FAM-GGS to tumor cells. D: CD11b and F4 / 80 positive cell populations within FAM-CRV positive cells. E) Flow cytometric analysis of cells isolated from 4T1 tumors after in vivo FAM-CRV translocation. Tumors were obtained 15 or 60 min after intravenous administration of FAM-CRV. Cells were incubated with CD11b and F4 / 80 primary and secondary antibodies for 1 h at 4 °C, washed, and analyzed by flow cytometry. [Figure 4] Figure 4 depicts the assessment of FAM-CRV binding with macrophages within atherosclerotic plaques. A) In vivo migratory colonization of FAM-CRV, FAM-ARA (negative control) or FAM-LyP-1 (positive control) in ApoE- / - mice bearing atherosclerotic plaques in the aorta. 100 μg of FAM-CRV, FAM-LyP1 or FAM-ARA were injected intravenously for 1 h circulation. Aorta (middle), kidney (right) and liver (left) were excised and imaged with a UV illuminator. B) Ex vivo staining with FAM-CRV or FAM-GGS isolated from aorta bearing plaques. Cells were incubated for 1 h at 4 °C and then analyzed by flow cytometry. [Diagram 5]Figure 5 depicts the evaluation of RXRB as a CRV binding receptor. A) High FAM-CRV binding with human immobilized recombinant RXRB protein compared to FAM-GGS. B) Cessation of CRV binding with RAW inhibited by RXRB for 1 h at 4 °C. C) Immunohistochemical staining of RXRB on 4T1 tumors with in vivo FAM-CRV or FAM-GGS translocational colonization. RXRB IHC staining colocalized with FAM-CRV and CD11b from immunofluorescence staining. D-F) Ex vivo CRV binding with cells isolated from 4T1 tumors. Cells were stained with FAM-CRV or FAM-GGS, CD11b, CD68, F4 / 80, and RXRB primary and secondary antibodies for 1 h at 4 °C. Cells were washed and analyzed by flow cytometry. G) Staining of cells after in vivo FAM-CRV translocational colonization. Tumors were obtained 60 min after intravenous administration of FAM-CRV. Cells were incubated with RXRB, CD11b, and F4 / 80 primary and secondary antibodies for 1 h at 4°C. Cells were washed and analyzed by flow cytometry. [Figure 6] Figure 6 depicts immunofluorescence staining of 4T1 mouse tissues with RXRB antibody and in vivo FAM-CRV migratory colonization. Tissue sections from 4T1 orthotopic tumor-bearing mice were stained with anti-FITC (fuchsia), anti-RXRB antibody or control rabbit IgG (green), anti-CD11b, CD68, F4 / 80 or CD31 antibodies (red) and DAPI (blue). The last column shows merged images from control IgG-recipient animals. [Figure 7] Figure 7 depicts CRV-pSiNP migratory colonization. A) Fluorescence imaging of tissues from 4T1 mice after 1 h of NP circulation. Top row: mice injected with pSiNPs. Bottom row: mice injected with CRV-pSiNPs. B) Flow cytometry analysis of cells isolated from 4T1 tumors after in vivo CRV-pSiNP or pSiNP migratory colonization. Tumors were obtained 60 min after intravenous administration. Cells were incubated with CD11b and CD68 primary and secondary antibodies for 1 h at 4 °C, washed, and analyzed by flow cytometry. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] Macrophages and the tumor microenvironment In vivo, the tumor microenvironment is a complex environment that includes numerous cell types, including tumor cells, vascular cells such as endothelial cells, and stromal cells such as fibroblasts. Furthermore, in vivo, these cells are exposed to the bloodstream and various biological delivery conditions. In vivo, microvascular cells in tumors are influenced by the bloodstream and communicate with tumor and non-tumor cells through physical and diffusive factors. Furthermore, tumor vasculature is abnormal, characterized by disorganized branching, low flow, and leaky capillaries, thus acting as a major delivery barrier for anti-cancer therapies targeted to tumor cells. The interaction of tumor cells with endothelial and stromal cells influences each cell type, enhancing angiogenesis and tumor cell proliferation. This crosstalk can be an important factor in determining tumor cell responsiveness to anti-cancer drugs.
[0017] In the tumor microenvironment, cells experience oxygen and nutrient deprivation. Hypoxic stress alters the metabolism of tumor cells and macrophages within the tumor, followed by changes in the microenvironment. The changes in the microenvironment alter the phenotype and metabolism of macrophages to induce tumor-promoting reprogramming. Nutrient stress also triggers autophagy to ensure cell survival or induce cell death. Tumor cell death is a communication system that attracts macrophages and governs their phenotype. Depending on the form of tumor cell death, macrophage polarization ranges from pro-inflammatory to anti-inflammatory / immunosuppressive activation.
[0018] Chronic inflammation contributes to cancer growth. The presence and activation of chronic innate immune cell types (e.g., neutrophils, macrophages, and mast cells) promotes cancer growth. It is therefore evident that some subpopulations of chronically activated innate cells promote the growth and / or survival of neoplastic cells. Depending on their polarization state, immune cells can exert either antitumor functions (e.g., T helper cell 1 (Th1) vs Th17 subpopulations of type I CD4(+) T cells) or tumor-sustaining functions (e.g., vs type II NKT cells, M1 vs M2 macrophages, and N1 vs N2 neutrophils). Chronically activated and polarized immune cells (e.g., M2 macrophages and N2 neutrophils) produce or possess a myriad of chemokines, cytokines, growth factors, and proteases that result in tissue remodeling, angiogenesis, cell proliferation, genomic instability, and the expansion of neoplastic cells into ectopic tissues.
[0019] Macrophages are a type of white blood cell in the immune system that engulf and digest cellular debris, foreign bodies, microorganisms, cancer cells, and anything that does not have the types of proteins specific to healthy body cells on its surface in a process called phagocytosis. Macrophages increase inflammation and stimulate the immune system. Macrophages can also play an important anti-inflammatory role and reduce immune responses by releasing cytokines. Macrophages that promote inflammation are called M1 macrophages, while macrophages that reduce inflammation and promote tissue repair are called M2 macrophages. Macrophages are the predominant immune cell population in most solid tumors. Tumor-associated macrophages (TAMs) are a type of macrophage. TAMs are thought to be responsible for tumor growth and progression and acquire the M2 phenotype. TAMs can regulate tumor progression. Therapeutic strategies to decrease TAM numbers or manipulate TAM phenotype are of interest in cancer treatment. Retinoid X receptors (RXRs) are members of the nuclear receptor superfamily and have essential nuclear and cytoplasmic functions as transcription factors. RXRs are a type of nuclear receptor that is activated by 9-cis retinoic acid, which is considered to be endogenously relevant. RXRs are also activated by 9-cis-13,14-dihydroretinoic acid, which may be the main endogenous mammalian RXR selective agonist. There are three retinoic X receptors (RXRs), namely, RXR alpha (RXRA), RXR beta (RXRB) and RXR gamma (RXRG), which are encoded by the RXRA, RXRB and RXRG genes, respectively. RXRs are heterodimerization partners for members of the type II subfamily of nuclear receptors that regulate the transcription of numerous target genes after selective activation. RXRs can heterodimerize with type I subfamily of nuclear receptors, including CAR, FXR, LXR, PPAR, PXR, RAR, TR and VDR. In the absence of ligand, RXR heterodimers are bound to hormone response elements complexed with inhibitory complement proteins. Binding of agonist ligands to RXR results in dissociation of inhibitory complement and recruitment of coactivator proteins.This promotes the transcription of downstream target genes into mRNA and ultimately protein. RXR can regulate macrophages in inflammatory and metabolic disorders, and the possibility exists to directly modulate RXR signaling for the treatment of macrophage-related pathologies. Cell surface expression of RXRB is specific for TAMs, and RXRB is due to the selective binding of CRV and other considered molecules to tumor macrophages.
[0020] Molecules that target TAMs The peptide CRV (CRVLRSGSC) is a cyclic macrophage targeting peptide with a disulfide bond between the terminal cysteine residues. CRV selectively migrates to tumors and binds to TAMs within the tumor. CRV recognizes and binds to RXRB on the surface of TAMs within the tumor. CRV only recognizes TAMs and does not recognize macrophages within atherosclerotic plaques.
[0021] The CRV can be conjugated to a therapeutic agent, which may include an antibody (e.g., IgG, IgA or IgM).
[0022] CRV can be modified to generate related peptides that are also considered to act as TAM molecules. Examples of such modifications include one or more substitutions, deletions, or additions of amino acids. Conservative substitutions include amino acid substitutions that replace a given amino acid with another amino acid of similar characteristics, and further include substitutions of hydroxyl residues serine and threonine, exchanges of acidic residues aspartate and glutameth, substitutions of amide residues asparagine and glutamine, exchanges of basic residues lysine and arginine, and substitutions between aromatic residues phenylalanine and tyrosine, among other aliphatic amino acid substitutions of alanine, valine, leucine, and isoleucine. In some embodiments, CRV is modified by one or more conservative amino acid substitutions. In other embodiments, CRV is modified by one conservative amino acid substitution.
[0023] Other TAM-binding molecules that can act as RXRB-binding molecules on the cell surface to selectively bind to TAM include antibodies (e.g., IgG, IgA, or IgM), antigen-binding fragments, peptides, ligands, non-IG domains, or small molecules. The TAM-binding molecules may bind to RXRB at different positions on the RXRB molecule. When the TAM-binding molecule is an antibody, it can be a single domain antibody, a chimeric antibody, a humanized antibody, a human antibody, and / or a monoclonal antibody. When the TAM-binding molecule is an antigen-binding fragment, it can be a Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, or a bispecific antibody. When the TAM-binding molecule is a peptide, it can be cyclic. When the TAM-binding molecule is cyclic, it can be CRV or another peptide.
[0024] Modifications to the TAM binding molecules are contemplated. These modifications include conjugation with a complementary moiety. The moiety may be a therapeutic or diagnostic agent used clinically or for research purposes.
[0025] These modifications can further construct a delivery system that can deliver the TAM-binding molecule to the tumor or tumor microenvironment in a targeted manner, the advantages of which may include less frequent administration to the patient, more uniform efficacy of the drug, fewer drug side effects, and less fluctuation in circulating drug concentrations.
[0026] The moiety, the TAM-binding molecule, or both, can be carried in a delivery agent, which can be a liposome, a microsphere, a nanoparticle, a microemulsion, a microcapsule, a polymer matrix, a hydrogel, or a viral vector.
[0027] Liposomes are non-toxic, non-hemolytic, and non-immunogenic even after repeated injections; they are biocompatible and biodegradable, and can be designed to avoid clearance mechanisms (reticuloendothelial system (RES), renal clearance, chemical or enzymatic inactivation, or other undesirable effects). Lipid-based, ligand-coated nanocarriers can store their deliveries in a hydrophobic shell or hydrophilic interior, depending on the nature of the drug being carried.
[0028] Microspheres can contain many drug classes, including small molecules, proteins, and nucleic acids, and are easily administered by needle injection. Microspheres are generally biocompatible, can provide high bioavailability, and can be sustained-released over long periods of time. Disadvantages of microspheres include the difficulty of large-scale manufacturing, drug inactivation during fabrication, and poor control of drug release rate.
[0029] Nanoparticle-based drug delivery systems are considered to be an effective method for delivering drugs. Some of the advantages of using nanoparticles include tunable release of the drug into the cytoplasm and avoidance of tumor drug resistance.
[0030] Microemulsions are thermodynamically stable, isotropic, transparent (or translucent) systems of oil, water and surfactants, often combined with co-surfactants with droplets of sizes in the range of 20-200 nm overall. Depending on their structure, said microemulsions can be classified as oil-in-water (o / w), water-in-oil (w / o) or co-continuous systems, characterized by extremely low interfacial tension between the oil and aqueous phases. Said systems are currently of great technical and scientific interest to researchers due to the possibility of incorporating a wide range of drug molecules (hydrophilic and hydrophobic) due to the presence of both lipophilic and hydrophilic domains. These adaptable delivery systems provide protection from oxidation, enzymatic hydrolysis, improve the solubilization of lipophilic drugs and thus their bioavailability. Microemulsions are suitable for oral and intravenous delivery systems, and for sustained and targeted delivery (e.g., via ocular, dental, pulmonary, vaginal and topical routes). Microemulsions are used to improve the oral bioavailability of various poorly soluble drugs. In some instances, microemulsions are used for such challenges as delivery of chemotherapy drugs to neoplastic cells and oral delivery of insulin. Microcapsules are particles with diameters of 1-1000 μm, regardless of precise internal or external structure, that can be used for drug delivery. Microcapsules offer a variety of important advantages as drug delivery systems, such as effective protection against degradation (e.g., enzymatic degradation) of the encapsulated active agent, the possibility of precise control of the release rate of the incorporated drug over a period ranging from hours to months, ease of administration (compared to alternative parenteral controlled release dosage forms such as macro-sized implants), and the ability to provide desired pre-programmed drug release profiles to meet the patient's therapeutic needs.
[0031] Drugs can be embedded in the polymer matrix or co-crystallized with the polymer template. Polymers are a drug delivery technology that provide controlled release of therapeutic agents at constant doses over extended periods of time, circulating administration, and tunable release of hydrophilic and hydrophobic drugs. Polymer matrices may be tailored for specific cargoes and engineered to perform distinct biological functions.
[0032] Hydrogels are three-dimensional crosslinked networks of water-soluble polymers. Hydrogels can be made from virtually any water-soluble polymer, thereby encompassing a wide range of chemical configurations and a plethora of physical properties. Furthermore, hydrogels can be formulated in a variety of physical forms, including slabs, microparticles, nanoparticles, coatings, and films. As a result, hydrogels are commonly used in clinical practice and experimental medicine for a wide range of applications, including tissue engineering and regenerative medicine, diagnostics, cell immobilization, biomolecule or cell separation, and barrier materials to modulate bioadhesion.
[0033] Viral delivery vectors are one type of nanomaterial that can be a potential drug delivery material. Effective vectors must be able to effectively carry and subsequently deliver their drug cargo to a specific target.
[0034] The conjugation can be achieved directly or indirectly, and with or without a linker molecule. The linker molecule can be a pH-sensitive linker, a disulfide linker, a peptide linker, a beta-glucuronide linker, a redox-reactive linker, a hydrazone linker, a hydrophilic linker, an azo linker, or another type of linker. The linker can be responsive to a stimulus to initiate drug release. The stimulus can be internal or external. The stimulus can be local. The stimulus can be pH, an enzyme, light, heat, or another stimulus.
[0035] When a TAM-binding molecule is conjugated to a moiety that is a therapeutic agent, the therapeutic agent can be a cytotoxic agent (e.g., a ribosome-inactivating protein, a histone deacetylase inhibitor, a tubulin inhibitor, an alkylating agent, an antibiotic, an antitumor agent, an antiproliferative agent, an antimetabolite, a type I or type II topoisomerase inhibitor, a hormone agonist or antagonist, an immunomodulatory agent, a DNA minor groove binder, or a radioactive agent), a chemotherapeutic agent (e.g., an alkylating agent, an anthracycline, a taxane, an epothilone, a type I or type II topoisomerase inhibitor, a histone deacetylase inhibitor, a kinase inhibitor, a nucleotide analog, a peptide antibiotic, a platinum-based agent, a retinoid, a vinca alkaloid or a translocation derivative thereof, or other chemotherapeutic agent), a protein, a peptide, an antibody, a growth inhibitory agent, a nucleic acid, or an anti-hormonal agent.
[0036] When a TAM binding molecule is conjugated to a moiety that is a diagnostic agent, the diagnostic agent may be a label, which may be a fluorescent label, a chromogenic label, or a radioactive label, and it is contemplated that the label will be used in diagnostic imaging (e.g., PET or MRI imaging, or imaging protocols incorporating PET or MRI). EXAMPLES
[0037] Example 1: CRV specifically binds to macrophages in vitro RAW (tumor-derived mouse macrophage cell line RAW264.7), J774 (tumor-derived mouse macrophage cell line J774A.1), THP-1 differentiated macrophages (human macrophages differentiated from the human monocytic cell line THP-1), and 4T1 (mouse breast cancer cell line) cells were cultured in DMEM supplemented with 10% FCS at 1 × 10 6The cells were incubated with FAM-CRV or the control peptide FAM-GGS (10 μM) in 300 μL of complete growth medium in an Eppendorf tube. After 1 h of incubation at 4 °C, the peptide-containing medium was removed by centrifugation and the cells were washed twice with PBS. Then, 100 μL of PFA (4% buffer) was added to the cells for fixation, and flow cytometry data were obtained with a FACSCanto (BD Biosciences, San Jose). The experiment was repeated three times on separate days.
[0038] FAM-CRV showed much higher binding to RAW, J774, and THP-1 differentiated macrophages than the control peptide FAM-GGS (Figure 1A). In contrast, FAM-CRV showed very limited binding to the 4T1 breast cancer cell line. These results demonstrated that CRV specifically binds to macrophages in vitro.
[0039] Example 2: CRV binding to macrophages in vivo To investigate whether CRV can bind to macrophages in vivo, FAM-CRV was injected intravenously into tumor-bearing mice. For this purpose, 4T1 and MCF10CA1a human breast cancer cells, and KRAS ink mouse PDAC cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Py8119 cells were cultured in Ham's F12K medium containing 5% FCS, 2.5 μg / mL amphotericin B, 50 μg / mL gentamicin, and MITO+. Human cell lines were authenticated by the DNA Analysis Core Facility at Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA), and KRAS ink cell lines were authenticated by DDC Medical (Fairfield, OH). All cells tested were negative for mycoplasma contamination. To generate 4T1 tumors, 1 × 10 610 tumor cells (suspended in 100 μL of PBS) were orthotopically injected into the mammary fat pad of normal BALB / c mice. To generate MCF10CA1a tumors, 2 × 10 6 1 × 10 tumor cells (suspended in 100 μL of PB) were orthotopically injected into the mammary fat pad of female BALB / c athymic nude mice. To generate Py8119 tumors, 1 × 10 6 1 × 10 tumor cells (suspended in 100 μL of PBS) were orthotopically injected into the mammary fat pad of C57BL6 mice. To generate KRAS-ink PDAC tumors, 1 × 10 6 To generate H1975 tumors, 1 × 10 cells were injected into female BALB / c mice. 6 of cells (suspended in 100 μL of PBS) were injected. (Which mouse species? Where was it injected?) All animal studies were approved by the Animal Research Committee of the Sanford Burnham Prebys Medical Discovery Institute.
[0040] The biodistribution of fluorescein-conjugated peptides (FAM-CRV, FAM-GGS or FAM-ARA) was examined after intravenous injection of 100 μL of peptide solution (1 mg / mL in PBS) into the tail vein of mice. Peptides were allowed to circulate for 1 h and transcardial perfusion was performed with PBS. Tissues were collected and fixed in 4% formaldehyde buffer and later immersed in 30% sucrose in PBS overnight.
[0041] The tumor models tested in this study are summarized in Table 1. For FAM-CRV migratory colonization, orthotopic 4T1 breast cancer, orthotopic MCF10CA1a breast cancer, subcutaneous kras-INK pancreatic cancer, subcutaneous KPC pancreatic cancer, and subcutaneous H1975 lung cancer were positive. Compared with other organs, the tumors displayed strong fluorescent signals under UV illumination.
[0042] [Table 1]
[0043] Representative images of 1-h translocation and colonization of FAM-CRV in a 4T1 breast cancer mouse model are shown in Figure 1B. FAM-CRV was primarily observed in tumors and kidneys, with moderate to low accumulation in the liver and spleen, which have high volumes of monocytes / macrophages. Similar biodistribution was observed in other CRV-positive models. These results suggested that FAM-CRV preferentially translocates and colonizes tumors over other macrophage-rich organs.
[0044] Example 3: Intratumoral migration and colonization of CRV FAM-CRV was injected intravenously into tumor-bearing mice. For this purpose, 4T1 human breast cancer cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. The human cell line was authenticated by the DNA Analysis Core Facility at the Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA), and the cell line was negative for mycoplasma contamination. To generate 4T1 tumors, 1 × 10 6 Tumor cells (suspended in 100 μL of PBS) were orthotopically injected into the mammary fat pad of normal BALB / c mice. All animal studies were approved by the Animal Research Committee of the Sanford Burnham Prebys Medical Discovery Institute.
[0045] The biodistribution of fluorescein-conjugated peptides (FAM-CRV, FAM-GGS or FAM-ARA) was examined after intravenous injection of 100 μL of peptide solution (1 mg / mL in PBS) into the tail vein of mice. Peptides were allowed to circulate for 1 h and transcardial perfusion was performed with PBS. Tissues were collected and fixed in 4% formaldehyde buffer and later immersed overnight in 30% sucrose in PBS. Tissues were finally frozen in OCT embedding medium (Tissue-Tek) and sliced for immunofluorescence staining.
[0046] Tissue sections were blocked in 1% bovine serum albumin with 0.1% Triton X-100 for 1 h and incubated with the appropriate primary and secondary antibodies. Blood vessels were visualized by staining of tissue sections with a monoclonal antibody against CD-31. The primary antibody was rat anti-mouse CD31 (BD Biosciences). The secondary antibody was 594 donkey anti-rat IgG from Invitrogen. After washing with PBS, sections were embedded in DAPI-containing mounting medium (Vector Laboratories, Burlingame, CA) and examined with a Zeiss LSM 710 NLO confocal microscope.
[0047] Immunofluorescence staining was performed for FAM-CRV and CD31 on all tissue sections. Representative images from the 4T1 breast cancer model are shown in Figure 2. CRV migrated to and spread within the tumor. In the tumor, the peptide could leave the blood vessel within 5 min after administration, as very small FAM-CRV signal was colocalized with CD31 staining (Figure 2A). At different migration time points (5 min, 15 min, and 60 min), the signal of FAM-CRV gradually increased in the tumor. This indicated that the peptide penetrated into the interstitium via the blood vessels. In comparison, the FAM-labeled control peptide GGS (GGSGGSKG) did not cause any fluorescent signal in the tumor at all time points. Interestingly, FAM-CRV was found to accumulate in other organs such as the liver, spleen, and lymph nodes after 5 min of circulation, but was rapidly washed out after 1 h.
[0048] Example 4: CRV targets macrophages within tumors To determine whether CRV targeted macrophages or other cell types within the tumors, tissue sections from 4T1 tumor-bearing mice were also stained for macrophage markers, including CD11b, F4 / 80, and CD68. To this end, 4T1 human breast cancer cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. Human cell lines were authenticated by the DNA Analysis Core Facility at the Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA), and the cell lines were negative for mycoplasma contamination. To generate 4T1 tumors, 1 × 10 6 Tumor cells (suspended in 100 μL of PBS) were orthotopically injected into the mammary fat pad of normal BALB / c mice. All animal studies were approved by the Animal Research Committee of the Sanford Burnham Prebys Medical Discovery Institute.
[0049] The biodistribution of fluorescein-conjugated peptides (FAM-CRV, FAM-GGS or FAM-ARA) was examined after intravenous injection of 100 μL of peptide solution (1 mg / mL in PBS) into the tail vein of mice. Peptides were allowed to circulate for 1 h and transcardial perfusion was performed with PBS. Tissues were collected and fixed in 4% formaldehyde buffer and later immersed overnight in 30% sucrose in PBS. Tissues were finally frozen in OCT embedding medium (Tissue-Tek) and sliced for immunofluorescence staining.
[0050] Tissue sections were blocked in 1% bovine serum albumin with 0.1% Triton X-100 for 1 h and incubated with the appropriate primary and secondary antibodies. Primary antibodies were rat anti-mouse CD11b (BD Biosciences), rat anti-mouse F4 / 80 monoclonal (BD Biosciences), and rabbit anti-fluorescein / Oregon Green (Invitrogen) polyclonal antibodies. Secondary antibodies were Alexa Fluor 488 goat anti-rabbit IgG and 594 donkey anti-rat IgG from Invitrogen. After washing in PBS, sections were embedded in DAPI-containing mounting medium (Vector Laboratories, Burlingame, CA) and examined with a Zeiss LSM 710 NLO confocal microscope.
[0051] Mice with tumor size of approximately 8 mm were euthanized by cervical dislocation under deep anesthesia (Avertin, no response to toe pinch). Target (tumor) and control (e.g. liver, spleen) tissues were collected and further dissociated into single cells. Tumor cells were isolated using the MACS tumor dissociation kit. Then, cells were incubated with fluorescently labeled CRV or other cell markers (CD11b, CD68, F4 / 80, FAB, EpCAM, CD31) for 1 h at 4 °C. Positive cells were quantified on a BD LSRFORTESSA and data were analyzed using FCS Express Version 3 (De Novo Software).
[0052] As shown in Figure 3A, the FAM-CRV signals strongly overlapped with those macrophage markers. This suggested that the accumulation of FAM-CRV in the tumor was mainly due to its association with tumor macrophages. Immunofluorescence staining was also performed on other animal models, with the same results. To further verify, cells were also isolated from the tumor, spleen, liver and blood of 4T1 tumor mice and incubated with FAM-CRV for ex vivo binding studies. In the 4T1 model, tumor cells manifested much higher FAM-CRV binding compared to spleen and blood cells, thereby confirming the preferential migratory colonization of FAM-CRV into the tumor (Figure 3B). In comparison, the control FAM-GGS peptide failed to specifically label macrophages in the tumor (Figure 3C). Compared to other tumor cells, there were approximately 15% of single tumor cells that showed very high FAM-CRV signals, which were designated as FAM-CRV positive. More than 50% of FAM-CRV-positive cells were positively stained for both CD11b and F4 / 80 (Figure 3D). The low CRV binding to blood and splenocytes further suggested that FAM-CRV recognized and extravasated tumor blood vessels and bound to macrophages in tumor tissues, without binding to circulating monocytes / macrophages and migrating to and colonizing tumors.
[0053] Example 5: FAM-CRV preferentially binds to tumor-associated macrophages Flow cytometric analysis of isolated 4T1 tumor cells was further performed after in vivo migratory establishment of FAM-CRV (15 min or 60 min after intravenous administration). For this purpose, FAM-CRV was injected intravenously into tumor-bearing mice. For this purpose, 4T1 human breast cancer cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. The human cell lines were authenticated by the DNA Analysis Core Facility at the Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA), and the cell lines were negative for mycoplasma contamination. To generate 4T1 tumors, 1 × 106 Tumor cells (suspended in 100 μL of PBS) were orthotopically injected into the mammary fat pad of normal BALB / c mice. All animal studies were approved by the Animal Research Committee of the Sanford Burnham Prebys Medical Discovery Institute.
[0054] Fluorescein-conjugated peptides (100 μL, 1 mg / mL PBS) were injected intravenously into the tail vein of tumor-bearing mice. Peptides were allowed to circulate for 1 h. Mice were then euthanized by cervical dislocation under deep anesthesia (Avertin, unresponsive to toe pinch). Tumors were collected and further dissociated into single cells and incubated with different cell markers (CD11b, CD68, F4 / 80, FAB, EpCAM, CD31) for 1 h at 4 °C. Positive cells were quantified on a BD LSRFORTESSA and data were analyzed using FCS Express Version 3 (De Novo Software).
[0055] Compared to uninjected control animals, tumor cells from animals of both circulation lengths showed higher FAM-CRV signals (Figure 3E). Approximately 20% of the FAM-CRV positive cells were identified as macrophages, which was much less than the percentage in the in vitro binding study. The extensive staining and washing steps for the primary and secondary antibodies may have caused much of the weakly bound FAM-CRV to be detached. All of these binding results indicated that FAM-CRV could preferentially bind to tumor-associated macrophages.
[0056] Example 6: FAM-CRV does not specifically bind to macrophages within atherosclerotic plaques Since macrophages are present at other disease sites, such as atherosclerotic plaques, it is of interest to know whether CRV recognizes other pathological tissues that contain macrophages. Therefore, the in vivo migration and colonization of FAM-CRV was tested in ApoE- / - mice bearing atherosclerotic plaques in the aorta. Unlike LyP1, which migrates to both tumors and plaques via the p32 receptor and binds to macrophages, FAM-CRV did not migrate to aortic plaques after systemic administration (Figure 4A), suggesting that CRV can discriminate between macrophages and TAMs in atherosclerotic plaques in vivo. Immunofluorescence staining of aortas further did not observe FAM-CRV accumulation in plaques. Single cell suspensions were also obtained from mouse aortas bearing atherosclerotic plaques, and in vitro binding studies confirmed that FAM-CRV did not specifically bind to macrophages in plaques compared to FAM-GGS (Figure 4B). This feature makes CRV a desirable peptide for targeting macrophages for disease-specific applications.
[0057] Example 7: RXRB is responsible for CRV binding to macrophages The differences between CRV and LyP-1 suggest that CRV probably binds to different receptors for TAM recognition. Thus, the CRV receptor on macrophages was identified. To reduce the complexity, the cell membrane fraction of RAW cells was isolated and affinity chromatography performed to isolate the putative CRV receptor. For this purpose, CRV was immobilized on a column. Lysates of 4T1 tumor tissue and membrane proteins of RAW cells (isolated with the MemPERPlus kit from ThermoFisher) were utilized as independent sources of the two putative receptors. After washing with buffer and the control peptide GGS, the putative receptor was eluted with excess of free CRV peptide. Mass spectrometry then identified retinoid X receptor beta (RXRB) as the candidate receptor.
[0058] To confirm that RXRB binds to CRV, FAM-CRV binding was tested with human recombinant RXRB protein immobilized on a plate. Human RXRB recombinant protein (50 μL, 5 μg / mL) was immobilized overnight at 4 °C in a high-binding 96-well plate. Bovine serum albumin was used as a control protein. The protein solution was removed and washed once with PBS. Then, 1% BSA in PBS solution was added to the wells and incubated for 1 h at room temperature to block remaining available binding sites. After one wash with PBS, RXRB and BSA were incubated with FAM-CRV (100 μL, 1 μM) at room temperature for 1 h. The wells were washed three times with PBS and fluorescence was measured using a multiplate reader.
[0059] There was a significantly higher binding of the CRV peptide with RXRB compared to the control peptide FAM-GGS (Figure 5A). Meanwhile, none of the peptides bound to the control protein BSA. Both J774 and RAW cells showed high FAM-CRV binding along with high surface expression of RXRB, while tumor cell lines such as 4T1 and PPC1 have very limited surface expression of RXRB and low FAM-CRV binding. CRISPR was used to silence the expression of RXRB in RAW cells, and the binding of CRV peptide with those engineered cells was evaluated. As shown in Figure 5B, silencing the expression of RXRB reduced approximately 70% of FAM-CRV binding with wild-type RAW cells, which was quantified by flow cytometry after 1 hour of incubation. These in vitro results indicated that RXRB is responsible for CRV binding with macrophages.
[0060] Example 8: RXRB surface binding is important for CRV binding In addition, immunohistochemistry (IHC) staining of RXRB was performed on 4T1 tumor tissues. For this purpose, 4T1 human breast cancer cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin. The human cell line was authenticated by the DNA Analysis Core Facility at the Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA), and the cell line was negative for mycoplasma contamination. To generate 4T1 tumors, 1 × 10 6 Tumor cells (suspended in 100 μL of PBS) were orthotopically injected into the mammary fat pad of normal BALB / c mice. All animal studies were approved by the Animal Research Committee of the Sanford Burnham Prebys Medical Discovery Institute.
[0061] Tissue sections were blocked with 1% bovine serum albumin with 0.1% Triton X-100 for 1 h and incubated with the appropriate primary and secondary antibodies. Primary antibodies were rat anti-mouse CD11b (BD Biosciences), rat anti-mouse F4 / 80 monoclonal (BD Biosciences), and rabbit anti-fluorescein / Oregon Green (Invitrogen) polyclonal antibodies. Secondary antibodies, Alexa Fluor 488 goat anti-rabbit IgG and 594 donkey anti-rat IgG, were from Invitrogen. After washing with PBS, sections were embedded in mounting medium with DAPI (Vector Laboratories, Burlingame, CA) and examined with a Zeiss LSM 710NLO confocal microscope.
[0062] This experiment demonstrated that RXRB colocalized with FAM-CRV as well as with macrophage markers (CD11b, F4 / 80, and CD68) (Figure 5C). Moreover, it is noteworthy that RXRB staining (brown) was not only seen in the nucleus but also throughout the cell, supporting the idea that surface expression of RXRB is important for CRV binding.
[0063] Example 9: RXRB-positive cells enhanced CRV binding To further explore the correlation between CRV binding to macrophages and RXRB surface expression, ex vivo binding of CRV and RXRB antibodies to tumor cells isolated from the 4T1 tumor model was performed. Mice with tumor sizes of approximately 8 mm were euthanized by cervical dislocation under deep anesthesia (Avertin, unresponsive to toe pinch). Target (tumor) and control (e.g. liver, spleen) tissues were collected and further dissociated into single cells. Tumor cells were isolated using a MACS tumor isolation kit. Then, cells were incubated with fluorescently labeled CRV or other cell markers (CD11b, CD68, F4 / 80) for 1 h at 4 °C. Positive cells were quantified on a BD LSRFORTESSA and data were analyzed using FCS Express Version 3 (De Novo Software).
[0064] Flow cytometry analysis showed that approximately 15% of cells from the tumor were RXRB positive, and FAM-CRV bound initially to cells with high RXRB surface expression (Figure 5D). The majority of RXRB-positive cells (approximately 73%) were CD11b-positive and F4 / 80-positive (Figure 5E), indicating that they were mainly expressed by TAMs. 73% of FAM-CRV-positive tumor cells were CD11b-positive and RXRB-positive. Staining of tumor cells after 1 h of in vivo migration fixation with FAM-CRV further showed that RXRB-positive cells had higher CRV binding. However, due to FAM-CRV loss in multiple washing steps, the difference was reduced compared to the ex vivo binding results (Figure 5D).
[0065] Example 10: Major organs have different levels of RXRB expression The good correlation between RXRB and CRV leads to an increased interest in investigating RXRB surface expression in different tissues, which may explain the in vivo CRV biodistribution. Both RXRB antibody (or rabbit IgG as a control) and FAM-CRV were injected intravenously into the same mice (RXRB antibody: 4 h circulation; FAM-CRV: 1 h circulation), and RXRB presentation was evaluated after transcardial perfusion. Tissue sections were blocked for 1 h with 1% bovine serum albumin with 0.1% Triton X-100 and incubated with the appropriate primary and secondary antibodies. Blood vessels were visualized by staining of tissue sections with monoclonal antibodies against CD-31. Primary antibodies were murine anti-mouse CD31CD11b (BD Biosciences), murine anti-mouse CD11b (BD Biosciences), murine anti-mouse F4 / 80 monoclonal (BD Biosciences), and rabbit anti-fluorescein / Oregon Green (Invitrogen) polyclonal antibodies. Secondary antibodies, Alexa Fluor 488 goat anti-rabbit IgG and 594 donkey anti-mouse IgG, were from Invitrogen. After washing with PBS, sections were embedded in mounting medium containing DAPI (Vector Laboratories, Burlingame, CA) and examined with a Zeiss LSM 710 NLO confocal microscope.
[0066] Immunofluorescence staining of tissue sections showed that the main organs had different levels of RXRB expression. RXRB was not observed in the heart and lungs, but could be detected in the tumor, liver, spleen and kidney, while IgG control staining was not observed in any organ. FAM-CRV signal could be confirmed only in the tumor and kidney after 1 hour of circulation. In the tumor, where RXRB staining was highest among all organs, RXRB showed excellent colocalization with FAM-CRV and macrophage markers, which was best with CD11b, followed by CD68 and F4 / 80 (Figure 6). In the liver, RXRB expression was lower and colocalized mainly with CD31 and little with CD68. For the spleen, RXRB antibody was found in some of the red pulp regions, with less colocalization with CD68 and no colocalization with CD31 at all. RXRB expression was very low and mainly colocalized with CD31 in lymph nodes and kidneys. This may explain why FAM-CRV was rapidly washed out over time in these two organs. Notably, the results of RXRB antibody staining were similar with or without the use of Triton X-100 as a cell permeabilizing agent.
[0067] Example 11: RXRB is a surface marker with high specific expression on tumor macrophages 50 μg of rabbit anti-mouse RXRB antibody (GeneTex, diluted in PBS, total volume was 100 μL) was injected intravenously into each mouse (n=3). 50 μg of rabbit IgG per mouse was injected into the control group (n=3). Three hours later, FAM-CRV (100 μg in 100 μL) was injected into all animals. After 1 hour of circulation of FAM-CRV, animals were killed by transcardial perfusion. Tissues were collected, fixed and sliced as described above.
[0068] When RXRB antibody was injected intravenously alone into 4T1 mice (further 4 hours of circulation), the clear distribution of RXRB was similar to that of FAM-CRV co-injection, indicating that the presence of FAM-CRV did not affect RXRB recognition by the antibody. In other words, RXRB antibody did not block the in vivo binding of CRV to RXRB and vice versa. This indicated that FAM-CRV bound to a different binding site as RXRB antibody, which was consistent with what was observed in the in vitro binding study. These in vivo migration results indicated that RXRB is a good surface marker with high specific expression on tumor macrophages. Furthermore, it showed that RXRB antibody could preferentially migrate to tumors by intravenous injection, penetrate blood vessels, bind to macrophages in the extravascular area, and function as a targeting agent.
[0069] Example 12: CRV-mediated transport and retention of nanoparticles in tumors To explore the translational potential of CRV-targeting approaches, CRV-mediated migration and retention of nanoparticles into tumors was evaluated. There have been extensive studies demonstrating porous silicon nanoparticles (pSiNPs) as therapeutic carriers with controlled loading and release of various types of drugs (24, 25). Their high efficiency of drug loading and time-gated imaging properties make them particularly desirable as drug carriers.
[0070] For proof of concept studies, CRV-conjugated porous silicon nanoparticles (CRV-pSiNPs) were loaded with a red fluorescent probe, SR101, and the nanoparticles demonstrated a tumor-implanting effect in 4T1 tumor-bearing mice. 100-200uL of a solution containing CRV peptide, CRV-pSiNPs or a control non-specific peptide was injected into the tail vein of tumor-bearing mice with tumor sizes of approximately 8mm. After 5 minutes and within 24 hours of circulation, the mice are anesthetized and imaged by imaging equipment (e.g., Xenogen IVIS, Lightools light table, multiphoton LSM). If available, like Xenogen IVIS, the mice are anesthetized with isoflurane during imaging (implantation: flow rate 0.8-1.5l / min, isoflurane vaporizer 2-3%, maintenance: flow rate 0.4-0.8l / min, isoflurane vaporizer 2-3%). Afterwards, the mice are perfused with PBS. Tumor and control organs are collected and used for histological characterization and immunohistochemical evaluation.
[0071] Ex vivo IVIS imaging showed that there was higher SR101 intensity in the tumors of animals that received CRV-pSiNPs compared to control NPs (Figure 7A). Cells isolated from the tumors with flow cytometry analysis were also analyzed. In the CRV-pSiNP group, 74% of the CRV-pSiNP-positive cells were CD11b-positive and CD68-positive, while only 52.5% of the control pSiNP-positive cells were CD11b-positive and CD68-positive macrophages. This suggested that CRV-targeted NPs mimicked the migratory and colonizing ability of free peptides, and that the CRV-pSiNP system may deliver drugs to tumor-associated macrophages, thus improving clinical outcomes. Hence, CRV-pSiNPs can be loaded with drugs to modulate macrophage polarization and evaluate the therapeutic efficacy of tumor treatment.
[0072] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention. It will be understood that various alternatives to the embodiments of the invention may be utilized in practicing the invention described herein. The following claims define the scope of the invention, and it is intended that methods and structures within the scope of the claims, and their equivalents, be covered thereby.
Claims
1. A method of treating or diagnosing cancer in a subject comprising administering to the subject a pharmaceutical composition comprising a tumor-associated macrophage (TAM) binding molecule.
2. The method of claim 1 , wherein the TAM binding molecule binds to retinoid X receptor beta on a TAM.
3. The method of claim 1 , wherein the TAM binding molecule is a peptide, a ligand, an antibody, a non-IG domain, or a small molecule entity.
4. The method of claim 1 , wherein the TAM binding molecule is an antibody or an antigen-binding fragment thereof.
5. The method of claim 4 , wherein the antibody is an IgG, IgA or IgM antibody.
6. The method of claim 4 , wherein the antibody is a single domain antibody.
7. The method of claim 4 , wherein the antibody is a chimeric antibody, a humanized antibody, or a human antibody.
8. The method of claim 4 , wherein the antibody is a monoclonal antibody.
9. The method of claim 4, wherein the antigen-binding fragment is a Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2 or a bispecific antibody.
10. The method of claim 1 , wherein the TAM binding molecule is a peptide.
11. The method of claim 10 , wherein the peptide is cyclic.
12. 12. The method of claim 10 or claim 11, wherein the peptide comprises a) CRVLRSGSC, or b) CRVLRSGSC with at least one conservative amino acid substitution.
13. The method of claim 1 , wherein the TAM binding molecule is further conjugated to a moiety.
14. The method of claim 13 , wherein the moiety is a therapeutic or diagnostic agent.
15. 15. The method of claim 14, wherein the therapeutic agent is a cytotoxic agent, a chemotherapeutic agent, a protein, a peptide, an antibody, a growth inhibitory agent, a nucleic acid, or an anti-hormonal agent.
16. 15. The method of claim 14, wherein the cytotoxic agent is a ribosome-inactivating protein, a histone deacetylase (HDAC) inhibitor, a tubulin inhibitor, an alkylating agent, an antibiotic, an antitumor agent, an antiproliferative agent, an antimetabolite, a type I or type II topoisomerase inhibitor, a hormone agonist or antagonist, an immunomodulatory agent, a DNA minor groove binding agent, or a radioactive agent.
17. The method of claim 14 , wherein the diagnostic agent is a label.
18. 18. The method of claim 17, wherein the label is a fluorescent label, a chromogenic label or a radioactive label.
19. The method of claim 13 , wherein the TAM binding molecule is directly conjugated to the moiety.
20. The method of claim 13 , wherein the TAM binding molecule is indirectly conjugated to the moiety via a linker.
21. The method of claim 1 , wherein the composition further comprises a delivery agent.
22. 22. The method of claim 21, wherein the delivery agent comprises a liposome, a microsphere, a nanoparticle, a microemulsion, a microcapsule, a polymer matrix, a hydrogel, or a viral vector.
23. The method of claim 1 , wherein the TAM binding molecule is cytolytic to tumor cells.
24. The method of claim 1 , wherein the TAM-binding molecule inhibits tumor growth.
25. 10. The method of claim 1, wherein the cancer is selected from the group consisting of brain cancer, kidney cancer, ovarian cancer, prostate cancer, colon cancer, lung cancer, squamous cell carcinoma of the head and neck, and melanoma.
26. 10. The method of claim 1, wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially.
27. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with a second therapeutic agent.
28. 28. The method of claim 27, wherein the second therapeutic agent is a cancer chemotherapeutic agent, radiation therapy, a cytotoxic agent, another antibody, an NSAID, a corticosteroid, a nutritional supplement such as an antioxidant, or a combination thereof.
29. A pharmaceutical composition comprising a tumor-associated macrophage (TAM) binding molecule conjugated to a moiety and a delivery agent.
30. 30. The pharmaceutical composition of claim 29, wherein the TAM binding molecule binds to retinoid X receptor beta on a TAM.
31. 30. The pharmaceutical composition of claim 29, wherein the TAM binding molecule is a peptide, a ligand, an antibody, a non-IG domain, or a small molecule entity.
32. 30. The pharmaceutical composition of claim 29, wherein the TAM binding molecule is an antibody or an antigen-binding fragment thereof.
33. 33. The pharmaceutical composition of claim 32, wherein the antibody is an IgG, IgA or IgM antibody.
34. The pharmaceutical composition of claim 32, wherein the antibody is a single domain antibody.
35. 33. The pharmaceutical composition of claim 32, wherein the antibody is a chimeric antibody, a humanized antibody, or a human antibody.
36. The pharmaceutical composition of claim 32, wherein the antibody is a monoclonal antibody.
37. 33. The pharmaceutical composition of claim 32, wherein the antigen-binding fragment is a Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2 or a bispecific antibody.
38. 30. The pharmaceutical composition of claim 29, wherein the TAM binding molecule is a peptide.
39. 39. The pharmaceutical composition of claim 38, wherein the peptide is cyclic.
40. 40. The pharmaceutical composition of claim 38 or claim 39, wherein the peptide comprises a) CRVLRSGSC, or b) CRVLRSGSC with at least one conservative amino acid substitution.
41. 30. The pharmaceutical composition of claim 29, wherein the moiety is a therapeutic or diagnostic agent.
42. 42. The pharmaceutical composition of claim 41, wherein the therapeutic agent is a cytotoxic agent, a chemotherapeutic agent, a protein, a peptide, an antibody, a growth inhibitory agent, a nucleic acid, or an anti-hormonal agent.
43. 43. The pharmaceutical composition of claim 42, wherein the cytotoxic agent is a ribosome-inactivating protein, a histone deacetylase (HDAC) inhibitor, a tubulin inhibitor, an alkylating agent, an antibiotic, an antitumor agent, an antiproliferative agent, an antimetabolite, a type I or type II topoisomerase I or II inhibitor, a hormone agonist or antagonist, an immunomodulatory agent, a DNA minor groove binding agent, or a radioactive agent.
44. 42. The pharmaceutical composition of claim 41, wherein the diagnostic agent is a label.
45. 45. The pharmaceutical composition of claim 44, wherein the label is a fluorescent label, a chromogenic label or a radioactive label.
46. 30. The pharmaceutical composition of claim 29, wherein the TAM binding molecule is directly conjugated to the moiety.
47. 30. The pharmaceutical composition of claim 29, wherein the TAM binding molecule is indirectly conjugated to the moiety via a linker.
48. 30. The pharmaceutical composition of claim 29, wherein the delivery agent comprises a liposome, a microsphere, a nanoparticle, a microemulsion, a microcapsule, a polymer matrix, a hydrogel, or a viral vector.
49. A method for reducing the number of TAMs in a tumor microenvironment of a subject with cancer, comprising administering to the subject a pharmaceutical composition of claims 29-48, wherein the pharmaceutical composition is cytotoxic to TAMs.
50. A method for eliminating immune suppression within the tumor microenvironment of a subject bearing cancer, comprising administering to said subject a pharmaceutical composition of claims 29-48, wherein the pharmaceutical composition removes, reduces and / or neutralizes TAMs.
51. A method for repolarizing TAM from an M2 phenotype to an M1 phenotype in a subject bearing cancer, comprising administering to said subject a pharmaceutical composition according to claims 29-48, wherein the pharmaceutical composition repolarizes TAM from an M2 phenotype to an M1 phenotype.
52. A method for detecting cancer in a subject, comprising administering to the subject a pharmaceutical composition according to any one of claims 29 to 48.
53. A method for detecting tumor-associated macrophages in a subject, the method comprising the step of administering to the subject a pharmaceutical composition according to any one of claims 29 to 48.
54. A method for detecting a tumor microenvironment in a subject having cancer, comprising administering to said subject a pharmaceutical composition according to claims 29 to 48.
